237 related articles for article (PubMed ID: 30143553)
1. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.
Greene LI; Bruno TC; Christenson JL; D'Alessandro A; Culp-Hill R; Torkko K; Borges VF; Slansky JE; Richer JK
Mol Cancer Res; 2019 Jan; 17(1):131-139. PubMed ID: 30143553
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.
Solvay M; Holfelder P; Klaessens S; Pilotte L; Stroobant V; Lamy J; Naulaerts S; Spillier Q; Frédérick R; De Plaen E; Sers C; Opitz CA; Van den Eynde BJ; Zhu J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344101
[TBL] [Abstract][Full Text] [Related]
3. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
4. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression.
Rogers TJ; Christenson JL; Greene LI; O'Neill KI; Williams MM; Gordon MA; Nemkov T; D'Alessandro A; Degala GD; Shin J; Tan AC; Cittelly DM; Lambert JR; Richer JK
Mol Cancer Res; 2019 Jan; 17(1):30-41. PubMed ID: 30213797
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
Schramme F; Crosignani S; Frederix K; Hoffmann D; Pilotte L; Stroobant V; Preillon J; Driessens G; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):32-45. PubMed ID: 31806638
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.
Hoffmann D; Dvorakova T; Stroobant V; Bouzin C; Daumerie A; Solvay M; Klaessens S; Letellier MC; Renauld JC; van Baren N; Lelotte J; Marbaix E; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):19-31. PubMed ID: 31806639
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy.
Onesti CE; Boemer F; Josse C; Leduc S; Bours V; Jerusalem G
J Transl Med; 2019 Jul; 17(1):239. PubMed ID: 31337401
[TBL] [Abstract][Full Text] [Related]
9. IL-1β increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells.
Urata Y; Koga K; Hirota Y; Akiyama I; Izumi G; Takamura M; Nagai M; Harada M; Hirata T; Yoshino O; Kawana K; Fujii T; Osuga Y
Am J Reprod Immunol; 2014 Nov; 72(5):496-503. PubMed ID: 24974860
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer.
Ghafouri-Fard S; Taherian-Esfahani Z; Dashti S; Kholghi Oskooei V; Taheri M; Samsami M
Exp Mol Pathol; 2020 Jun; 114():104415. PubMed ID: 32165090
[TBL] [Abstract][Full Text] [Related]
11. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.
Carvajal-Hausdorf DE; Mani N; Velcheti V; Schalper KA; Rimm DL
J Immunother Cancer; 2017 Oct; 5(1):81. PubMed ID: 29037255
[TBL] [Abstract][Full Text] [Related]
12. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
14. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
15. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Pilotte L; Larrieu P; Stroobant V; Colau D; Dolusic E; Frédérick R; De Plaen E; Uyttenhove C; Wouters J; Masereel B; Van den Eynde BJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2497-502. PubMed ID: 22308364
[TBL] [Abstract][Full Text] [Related]
16. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.
Berthon C; Fontenay M; Corm S; Briche I; Allorge D; Hennart B; Lhermitte M; Quesnel B
Leuk Res; 2013 May; 37(5):573-9. PubMed ID: 23453284
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.
Mohapatra SR; Sadik A; Tykocinski LO; Dietze J; Poschet G; Heiland I; Opitz CA
Front Immunol; 2019; 10():2762. PubMed ID: 31866995
[TBL] [Abstract][Full Text] [Related]
18. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Ott M; Litzenburger UM; Rauschenbach KJ; Bunse L; Ochs K; Sahm F; Pusch S; Opitz CA; Blaes J; von Deimling A; Wick W; Platten M
Glia; 2015 Jan; 63(1):78-90. PubMed ID: 25132599
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis.
Hsu YL; Hung JY; Chiang SY; Jian SF; Wu CY; Lin YS; Tsai YM; Chou SH; Tsai MJ; Kuo PL
Oncotarget; 2016 May; 7(19):27584-98. PubMed ID: 27050278
[TBL] [Abstract][Full Text] [Related]
20. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]